u/ZZerozen

The author argues Crossject's ZENEO needle-free emergency auto-injector is validated by a signed BARDA framework worth up to $155M (roughly $60M firm initial stockpile order, ~$32M development funding, up to $63M in options) while the market cap sits near $100M, so investors are paying less than the committed US government contract value. The mechanism is that FDA Emergency Use Authorization for ZENEO ZEPIZURE (midazolam) would immediately trigger the initial BARDA stockpile order, de-risk the platform for defense and big-pharma partners, and open a multi-billion market across epilepsy, anaphylaxis and naloxone with a 400+ patent wall limiting competition. The author states main risks as historical delays and dilution common to small medtechs, while describing the timeframe loosely as 'over time' with a 2-5x scenario if the EUA is granted and execution is decent.